Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJDVCW)

Drug Name

HL-085 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting ERK activator kinase (MEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-162	DM1P6FR	Melanoma	2C30	Approved	[3]
NFX-179	DM77XQT	Neurofibromatosis 1	LD2D.10	Phase 2	[4]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
GDC-0623	DMDY08K	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
BI 3011441	DMFJGUL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
Pyridinone compound 1	DM2GR5Q	N. A.	N. A.	Patented	[8]
Quinazolines and azaquinazoline derivative 1	DME24BI	N. A.	N. A.	Patented	[8]
PMID28594589-Compound-TABLE3C2	DMVYG0U	N. A.	N. A.	Patented	[8]
Benzoheterocyclic compound 1	DM3K25J	N. A.	N. A.	Patented	[8]
Benzoimidazole derivative 1	DMUJFCK	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03973151) Study of HL-085 in NRAS Mutant Advanced Melanoma. U.S. National Institutes of Health.
2	Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	Clinical pipeline report, company report or official report of NFlection Therapeutics
5	Clinical pipeline report, company report or official report of Roche.
6	Clinical pipeline report, company report or official report of Genentech (2011).
7	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
8	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.